89Zr-DFO-daratumumab
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for 89Zr-DFO-daratumumab, covering 2021-07-30 to 2021-07-30. Get the full timeline:
Most recent: Clinical Trial Update: First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody [Phase 1, Phase 2]